LSD-based therapy succeeds in late-stage depression trial
Definium Therapeutics said on June 22 that its LSD-based pill, DT120, met its goals in a Phase 3 trial for major depression. Patients on the drug saw a 13.3-point decline on the Montgomery-Åsberg Depression Rating Scale at six weeks, compared with 5.2 points for placebo, and the benefit largely held at 12 weeks (about 11 points versus 3.6).
A positive Phase 3 result is the bar regulators typically require, so the data is a meaningful step toward a possible approval for a psychedelic medicine — a category that has produced promising mid-stage results but few late-stage wins. The field has also drawn unusual policy attention, with the Trump administration signaling support for psychedelic therapeutics. Full peer-reviewed data and the FDA’s read on trial design, including how effectively such studies can be blinded, will determine how far the result carries.